coverage from
i
What that date means
Coverage begins on 2026-08-10, which is when this archive started holding
Federal Register issues — not when the agency started publishing.
Anything earlier is absent from this page, and its absence is not evidence.
The Food and Drug Administration published four notices and one proposed rule on August 10, 2026, including determinations on baclofen oral solution and patent extension periods.
The FDA announced availability of final guidance for industry on minimizing biological hazards in ready-to-eat fresh-cut produce.
The Food and Drug Administration published notices announcing a hearing on a methylphenidate tablet approval withdrawal proposal and finalizing guidance on formal meetings with drug sponsors.
The Food and Drug Administration published two proposed rules on device classification and one final rule reclassifying in situ hybridization test systems, along with six notices regarding information collections and guidance.
The FDA published draft guidance on abbreviated drug application pathways and announced a public workshop on testosterone use in menopausal women.
FDA published three proposed rules on color additive petitions for gardenia blue, carrot oil, and safflower extract, and one final rule permitting chromium DL-methionine chelate in animal feed.
The FDA published four notices renewing two advisory committees and releasing draft and final guidance documents on potency assessment and cellular and gene therapy product development.
The Food and Drug Administration announced renewal of the Oncologic Drugs Advisory Committee for an additional two years until September 1, 2028.
The Food and Drug Administration published three notices regarding medical device standards recognition, product-specific drug guidances, and therapeutic equivalence evaluation guidance.
The FDA extended the effective date of its final resolution regarding estrogen-androgen fixed-combination drug products to November 4, 2026.
The Food and Drug Administration published six notices regarding information collection activities and draft guidance for animal drug compounding.
FDA issued three Emergency Use Authorizations for animal drugs to prevent and treat New World screwworm infestations in cattle, horses, swine, sheep, deer, dogs, cats, and kittens.
The FDA published a notice determining that NAMENDA memantine hydrochloride tablets were not withdrawn for safety or effectiveness reasons.
The FDA determined that Phenaphen with Codeine No. 3 and No. 4 oral capsules were not withdrawn for safety or effectiveness reasons.
The FDA published a notice requesting information on advancing botanical drug product development, with comments due November 3, 2026.
Ask an assistant instead
Everything on this page is also a tool call. Add
mcp.downstream.sh as an MCP server in Claude, ChatGPT, or any client that speaks the
protocol — no key, no account — then paste this:
Using the Downstream MCP server at mcp.downstream.sh, call whats_new_since with agency "Food and Drug Administration" since 2026-08-10, then tell me what this agency has been working on and which of its deadlines are still open.
Reaches whats_new_since. The response carries its own citations
and states what it is missing — including which dates it has no record for.